Still time to register
Register here »
Final program announced
View program here »
According to the first WHO Global report on diabetes, the incidence of type 2 diabetes, and its consequent metabolic sequelae, has essentially quadrupled since 1980 to 422 million adults worldwide. The underlying causes are complex though generally attributed to an alarming rise in obesity. There is an urgent need for effective therapies other than lifestyle changes that do not negatively impact cardiovascular health. Recent clinical reports of the safety and efficacy of the SGLT2 inhibitors, GLP-1 based agonism, and PCSK9 inhibitors, to name a few, have generated much hope and excitement. However, it is crucial that metabolic therapeutic research stays ahead of the curve. This meeting will address cutting-edge therapeutic pathways and key conceptual advances in targeting diabetes, obesity, fatty liver, and cardiovascular complications. Additionally, there will be a particular focus on novel technologies and ways in which they can be harnessed to combat metabolic complications.
Symposium themes:
- Metabolic precision medicine
- Diabetes
- Obesity
- Translating therapeutics for metabolic diseases
- Integrated energy metabolism
- David Chan, USA
- Sabrina Diano, USA
- Richard Di Marchi,USA
- Daniel Drucker, Canada
- Ronald Evans, USA
- Lora Heisler, UK
- Barbara Kahn, USA
- Michael Karin, USA
- Rob Knight, USA
- Ruth Loos, USA
- Christopher Newgard, USA
- Stephen O’Rahilly, UK
- Francesco Rubino, UK
- Kristina Schoonjans, Switzerland
- Bruce Spiegelman, USA
- Scott Sternson, USA
- Garret Stuber, USA
- Matthias Tschöp, Germany
- Jeffrey Friedman, Rockefeller University, USA
- Matthias Tschöp, Helmholtz Zentrum München, Germany
- Nikla Emambokus, Editor-in-Chief, Cell Metabolism
- Robert Kruger, Deputy Editor, Cell

Sitges, Spain

October 22 - 24, 2017
Banff, Canada

Arlington, VA, USA

February 11-14, 2018
Rehovot, Israel
September 17 - 19, 2017
Sitges, Spain
May 21 - 23, 2017
Gothenburg, Sweden